Fosfomycin/molgramostim (Reponex Pharmaceuticals)

N/A

Report date: 2025/01/07 17:01:02

Base Information

Drug NameFosfomycin/molgramostim (Reponex Pharmaceuticals)
Drug Alias NameRNX-023
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionGranulocyte-macrophage colony-stimulating factor receptor stimulantsPeptidoglycan inhibitorsCell wall inhibitors
TargetsGranulocyte-macrophage colony-stimulating factor receptorPeptidoglycan
Therapy Area/IndicationsSkin Ulcer
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsYes Molgramostim
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesReponex Pharmaceuticals As
China Registration ClassN/A

Develop Information

Active CompaniesReponex Pharmaceuticals As
Inactive CompaniesN/A
Active IndicationsSkin Ulcer
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A